Skip to main content
LIFECORE BIOMEDICAL, INC. \DE\ logo

LIFECORE BIOMEDICAL, INC. \DE\ — Investor Relations & Filings

Ticker · LFCR ISIN · US5147661046 LEI · 549300EHBZ5OM9ND9O43 US Manufacturing
Open in API
Filings indexed 1,096 across all filing types
Latest filing 2013-10-02 Director's Dealing
Country US United States of America
Listing US LFCR

About LIFECORE BIOMEDICAL, INC. \DE\

https://www.lifecore.com/

Lifecore Biomedical is an integrated contract development and manufacturing organization (CDMO) that specializes in sterile injectable pharmaceutical drug products and medical devices. The company provides a full range of services, including specialty formulation, process development, aseptic filling, and final packaging, supporting products from clinical phases through to commercial supply. A key area of expertise is the handling of complex and highly viscous formulations. In addition to its CDMO capabilities, Lifecore is a primary producer of non-animal-sourced sodium hyaluronate (hyaluronic acid), offering it in various molecular weights and formats, including bulk material, hydrogels, and filled syringes and vials for diverse applications.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2013-10-02 English
FORM 10-Q
Interim / Quarterly Report Q1 2014
2013-09-26 English
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated September 24, 2013, by Landec Corporation. It specifically states in Item 2.02 that the company issued a press release announcing its consolidated financial results for the first quarter of fiscal year 2014. The document includes the press release as Exhibit 99.1. The text indicates this is a current report announcing quarterly financial results, which aligns with an Earnings Release (ER). The document length is 3090 characters, which is short and typical for an 8-K earnings announcement. It is not a full interim report with detailed financial statements, so it does not qualify as an Interim/Quarterly Report (IR). It is also not a report publication announcement or a certification. Therefore, the best classification is Earnings Release (ER).
2013-09-24 English
FORM DEF 14A
Proxy Solicitation & Information Statement
2013-08-21 English
FORM 10-K
Annual Report FY 2013
2013-08-06 English
FORM 8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated July 25, 2013, reporting on the approval of a long-term incentive plan and a nonqualified deferred compensation plan by the Board of Directors. The content focuses on management compensation plans and changes related to directors and officers. There are no financial statements or detailed financial results presented. The key item reported is the approval of compensation-related plans and arrangements, which aligns with announcements about changes in management or board-related matters. Therefore, the document fits best under Board/Management Information (MANG). The document length is 3931 characters, which is typical for an 8-K filing focused on management changes or compensation plans rather than a full financial report or earnings release.
2013-07-31 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.